Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495709 | 1.00 | KMT2A (0.44) | KMT2AMEN1GAAPOLBMAPT | |
| SCHEMBL2714124 | 0.78 | KMT2A (0.56) | KMT2AMEN1GAAPOLBMAPT | |
| SCHEMBL30862164 | 0.78 | MEN1 (0.38) | KMT2AMEN1MAPTLMNAAHR | |
| SCHEMBL26341085 | 0.78 | MEN1 (0.38) | KMT2AMEN1MAPTLMNAAHR | |
| SCHEMBL6073377 | 0.78 | MEN1 (0.38) | KMT2AMEN1GAAMAPTLMNA | |
| SCHEMBL24339632 | 0.78 | MEN1 (0.38) | KMT2AMEN1MAPTLMNAAHR | |
| SCHEMBL29537852 | 0.78 | MEN1 (0.38) | KMT2AMEN1GAAMAPTLMNA | |
| SCHEMBL3257090 | 0.77 | KMT2A (0.46) | KMT2AMEN1GAAPOLBMAPT | |
| SCHEMBL29545354 | 0.77 | MEN1 (0.43) | KMT2AMEN1LMNAAHRNPC1 | |
| SCHEMBL9910955 | 0.77 | MEN1 (0.43) | KMT2AMEN1LMNAAHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283793-A | Synthesis process of 2-methylthio-4-chloro-5-bromopyrimidine | 南京哈柏医药科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-109843890-B | Application of triazolopyrimidine, triazolopyridine compound and composition thereof in treating PRC 2-mediated diseases | 中国科学院上海药物研究所 | 2022-03-29 | — | — | CN | claimed |
| EP-3689875-B1 | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-10-13 | — | — | EP | claimed |
| US-11013745-B2 | Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-05-25 | — | — | US | claimed |
| US-20200261459-A1 | TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND THE COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-08-20 | — | — | US | claimed |
| EP-3689875-A1 | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-08-05 | — | — | EP | claimed |
| US-20260146124-A1 | RESIN COMPOSITION AND USES OF THE SAME | TAIWAN UNION TECHNOLOGY CORPORATION (TW) | 2026-05-28 | — | — | US | disclosed |
| US-20260085154-A1 | POLYMER, COMPOSITION, CURED PRODUCT, LAMINATED BODY, AND ELECTRONIC COMPONENT | JSR CORPORATION (JP) | 2026-03-26 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250365860-A1 | COPPER-CLAD LAMINATE AND USES OF THE SAME | TAIWAN UNION TECHNOLOGY CORP (TW) | 2025-11-27 | — | — | US | disclosed |
| EP-4624471-A1 | PKMYT1 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| EP-4582423-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| EP-1565475-B1 | DIAZINOPYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-4384118-A | FUNGICIDES, BACTERICIDES | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1983-05-17 | — | — | US | disclosed |
| US-4330461-A | FIREPROOFING POLYESTERS AND POLYAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-05-18 | — | — | US | disclosed |
| US-4234729-A | FIREPROOFING POLYMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-4025510-A | DYES FOR POLYESTERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | KMT2A 2161/4885MEN1 2198/4885GAA 2759/4885 |
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | KMT2A 523/4885MEN1 1354/4885GAA 3527/4885 |
| US-20200261459-A1 | TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND THE COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | EED, EZH2, SUZ12 | KMT2A 66/4885MEN1 3054/4885GAA 2881/4885 |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | EED, CUL3, PSME3 | KMT2A 603/4885MEN1 2067/4885GAA 3693/4885 |
| US-20260146124-A1 | RESIN COMPOSITION AND USES OF THE SAME | ARCN1, ASH2L, ITGA1 | KMT2A 1264/4885MEN1 1187/4885GAA 4782/4885 |
| US-11013745-B2 | Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases | EED, EZH2, SUZ12 | KMT2A 66/4885MEN1 3054/4885GAA 2881/4885 |
| US-20260085154-A1 | POLYMER, COMPOSITION, CURED PRODUCT, LAMINATED BODY, AND ELECTRONIC COMPONENT | RER1, COL1A1, SMC1A | KMT2A 589/4885MEN1 1024/4885GAA 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.